Navigation Links
Unprecedented structural insights: NMDA receptors can be blocked to limit neurotoxicity
Date:1/22/2014

Cold Spring Harbor, NY Structural biologists at Cold Spring Harbor Laboratory (CSHL) and collaborators at Emory University have obtained important scientific results likely to advance efforts to develop new drugs targeting NMDA receptors in the brain.

NMDA (N-methyl D-aspartate) receptors are found on the surface of many nerve cells and are involved in signaling that is essential in basic brain functions including learning and memory formation. Problems with their function have been implicated in depression, schizophrenia, Alzheimer's and Parkinson's diseases, as well as brain damage caused by stroke.

Normally, NMDA receptors are activated by glutamate, the most common neurotransmitter of excitatory cell-to-cell messages in the brain.

Overactivation of NMDA receptors is a known cause of nerve-cell toxicity. Thus, drug developers have long sought compounds that can selectively block or antagonize NMDA receptors, while not affecting other types of glutamate receptors in the brain, whose function is essential. However, a basic question -- how those compounds bind and antagonize NMDA receptors -- has not been understood at the molecular level.

Over a period of years, CSHL Associate Professor Hiro Furukawa and colleagues have taken a step-by-step approach to learn about the precise shape of various subunits of the complex NMDA receptor protein, and demonstrating the relationship between different versions of the receptor's shape and its function. (see more here) Since the subunits have different biological roles, they have to be specifically targeted by drug compounds to obtain specific effects.

Furukawa's team has used a technique called x-ray crystallography to map various domains of the protein while it is bound to different chemical compounds, or antagonists, that downregulate its function. Today in the journal Neuron they publish the first crystal structures of two NMDA receptor subunits (called GluN1 and GluN2A) in complex with four different compounds known to have the capacity to inhibit, or antagonize, NMDA receptor function.

Showing this two-unit ligand binding domain (LBD) in complex with NMDA antagonists -- potential drugs -- reveals that each antagonist has a distinctive mode of binding the LBD. In essence, the "docking port" is held open, but to a different extent when different antagonists are bound. The study also reveals an element in the antagonist binding site that is only present in GluN2A subunit, but not in the others. This previously hidden information, says Furukawa, is critical: "It indicates different strategies to develop therapeutic compounds ones that bind to a certain type of NMDA receptors very specifically. Being able to target specific subtypes of the receptor is of enormous interest and has great therapeutic potential in a range of illnesses and injuries affecting the brain."


'/>"/>

Contact: Peter Tarr
tarr@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory
Source:Eurekalert  

Related medicine news :

1. Unprecedented accuracy in locating brain electrical activity with new device
2. UT MD Anderson Cancer Center launches unprecedented Moon Shots Program
3. Ibrutinib has unprecedented impact on mantle cell lymphoma
4. Premium Astrology Client Care Team Offers Unprecedented 24-Hour Turnaround Time During March 2013 Reader's Appreciation Month
5. Unprecedented Plastic Surgery SEO Guarantee Announced by JD Media Surge, LLC
6. bioMérieux Partners with Ultimate Labs to Bring Unprecedented Speed to Pathogen Identification for Food, Drug, and Cosmetic Manufacturers
7. Gang members found to suffer unprecedented levels of psychiatric illness
8. Pacific Prime Clients with Aetna Receive Unprecedented Discounts on First Year Insurance Premiums
9. New Hawaiian Jellys “Slip…aaahs” Sandals Provide Unprecedented Comfort and Fashion for Flip Flop Enthusiasts
10. CARRE Foundation selects TGen for unprecedented research into causes of multiple system atrophy
11. An Unprecedented Initiative to Hit Cancer Head On
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Unprecedented structural insights: NMDA receptors can be blocked to limit neurotoxicity
(Date:12/7/2016)... ... ... “Fred Rides a Train” allows readers to tag along on a special shopping trip ... the creation of published author, Janet Morrison, who has been writing mostly poetry, essays, ... Dog" series is her first attempt at writing for children. Janet, Fred, and two ...
(Date:12/7/2016)... ... 2016 , ... The Business Architecture Guild is ... on March 21-22, 2017. This premier event features business practitioners and experts from ... of industries such as financial services, insurance, healthcare, manufacturing, transportation, retail, and utilities. ...
(Date:12/7/2016)... ... December 07, 2016 , ... NuevaCare, a leading home care ... proud to announce new city-specific pages as part of its ambitious website relaunch. As ... often look, first, for local agencies serving their city. The new site has several ...
(Date:12/6/2016)... ... December 06, 2016 , ... People with ... be seen on a type of MRI, according to a study appearing online ... the central nervous system characterized by tremors or trembling and stiffness in the ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... of a higher risk of serious health problems, such as cardiovascular illness, according ... Peiman Soleymani of Beverly Hills Periodontics & Dental Implant Center notes that the ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016 Two new disaster drones ... a simulated mass casualty event Tuesday at John Bell ... technology debuted before an audience including Mississippi ... from Homeland Security, Federal Law Enforcement Agencies, and the ... as HiRO (Health Integrated Rescue Operations), was developed by ...
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, Inc. ... company, announced today that it entered into collaboration ... therapeutics for the treatment of NASH and other ... delivery platform LUNAR™ and UNA Oligomer chemistry. The ... Takeda,s long-standing commitment to and expertise in GI ...
(Date:12/6/2016)... Dec. 6, 2016  Blueprint Medicines Corporation (NASDAQ: ... targeted kinase medicines for patients with genomically defined diseases, ... offering of $125,000,000 million in shares of its common ... underwriters a 30-day option to purchase up to an ... stock in connection with the public offering. All shares ...
Breaking Medicine Technology: